Form 4: Zoetis Executive Vice President Reports Acquisition of Phantom Stock Units

Executive Vice President Jeannette Ferran Astorga reports acquiring phantom stock units in Zoetis through the company's Supplemental Savings Plan.

Summary

• Jeannette Ferran Astorga, an Executive Vice President at Zoetis Inc., filed a Form 4 on April 1, 2024, reporting a transaction that occurred on March 28, 2024.
• The transaction involved the acquisition of 173.5743 phantom stock units pursuant to the Zoetis Supplemental Savings Plan.
• The price per phantom stock unit was $54.33.
• Following the reported transaction, Astorga beneficially owns 982.8673 phantom stock units.
• These phantom stock units are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment fund at any time, provided Zoetis may limit the timing, frequency and permissibility of transfers from one investment fund to another at any time.
• Each phantom stock unit represents a fraction of a phantom share of Zoetis common stock, plus a small amount of cash-equivalent investments (the cash-equivalent investments typically represent around 5% of the total value of the phantom stock unit).

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing, so the sentiment is neutral. The acquisition of phantom stock units could be interpreted as a slightly positive sign of executive confidence.

Positives

• The acquisition of phantom stock units by an executive could be seen as a positive sign of confidence in the company's future performance.

Future Outlook

The phantom stock units are settled in cash following the reporting person's separation from service.

Industry Context

Executive compensation through stock and phantom stock units is a common practice in publicly traded companies to align management's interests with those of shareholders.

Comparison to Industry Standards

• Zoetis's executive compensation practices, including the use of phantom stock units, are generally in line with industry standards for large pharmaceutical companies.
• Companies like Eli Lilly, Merck, and Pfizer also utilize various forms of equity-based compensation for their executives.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns executive compensation with company performance.

Key Dates